Sartorius AG (MIL:1SRT3)
€ 238.1 0 (0%) Market Cap: 15.74 Bil Enterprise Value: 19.74 Bil PE Ratio: 178.54 PB Ratio: 5.11 GF Score: 70/100

Q2 2024 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript

Jul 18, 2024 / 11:00AM GMT
Release Date Price: €247.2 (+1.44%)
Joachim Kreuzburg
Sartorius AG - Chairman of the Executive Board, Chief Executive Officer

Welcome everyone, and thank you for dialing in at this little bit unusual time for our call on quarterly results. Obviously, this is because we pulled the publication forward in the context of our decision to de-risk our guidance and therefore ad hoc these news in the format of an ad hoc announcement just a little bit earlier today.

I would like to walk you through the highlights and the most important points for H1 of the Sartorius group, that largely also are relevant for Sartorius Stedim Biotech. I will then hand over to Florian, our CFO, who will walk you through the numbers in more detail.

Thereafter, I will talk a little bit more in detail about the revised guidance for full-year 2024. Then we will hand over to Rene who will talk about Sartorius Stedim Biotech for H1 as well as outlook. So as we also said for Q1, one can clearly say that we still see a very mixed picture regarding market conditions and how this reflects then in our numbers.

First of all, we have to say we did

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot